Crossbow Therapeutics, Inc
Emily McNally is a skilled scientist with a robust background in biomedical research, currently serving as Scientist I at Crossbow Therapeutics, Inc. since May 2024. Prior to this role, Emily held the position of Principal Research Associate at Clade Therapeutics and has garnered experience at Jounce Therapeutics, where roles included Senior Associate Scientist and Associate Scientist. Emily's earlier career includes various positions at SQZ Biotechnologies, culminating as Associate Scientist, and progressive roles at The Armanios Lab at Johns Hopkins School of Medicine, focusing on telomeres in disease. Emily earned a Bachelor of Science in Biomedical Engineering from The Johns Hopkins University.
Crossbow Therapeutics, Inc
Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.